Knapp FF[au] - Search Results

Year	Number of Results
1969	2
1970	1
1972	1
1974	2
1975	2
1976	2
1978	2
1979	1
1980	3
1981	3
1982	3
1983	4
1984	6
1985	8
1986	7
1987	2
1988	3
1989	6
1990	1
1991	4
1992	3
1993	5
1994	6
1995	6
1996	10
1997	12
1998	12
1999	12
2000	14
2001	8
2002	2
2003	5
2004	1
2006	1
2007	2
2008	1
2011	2
2012	5
2013	4
2015	8
2016	1
2018	1
2019	1
2020	1
2022	0

1

Targeted radionuclide therapy--an overview.

Dash A, Knapp FF, Pillai MR. Dash A, et al. Among authors: knapp ff. Curr Radiopharm. 2013 Sep;6(3):152-80. doi: 10.2174/18744710113066660023. Curr Radiopharm. 2013. PMID: 24059327 Review.

2

BMIPP-design and development.

Knapp FF Jr, Kropp J. Knapp FF Jr, et al. Int J Card Imaging. 1999 Feb;15(1):1-9. doi: 10.1023/a:1006147228352. Int J Card Imaging. 1999. PMID: 10453397 Review.

3

Peptide receptor radionuclide therapy: an overview.

Dash A, Chakraborty S, Pillai MR, Knapp FF Jr. Dash A, et al. Among authors: knapp ff jr. Cancer Biother Radiopharm. 2015 Mar;30(2):47-71. doi: 10.1089/cbr.2014.1741. Epub 2015 Feb 24. Cancer Biother Radiopharm. 2015. PMID: 25710506 Review.

4

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives.

Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr. Lepareur N, et al. Among authors: knapp ffr jr. Front Med (Lausanne). 2019 Jun 14;6:132. doi: 10.3389/fmed.2019.00132. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31259173 Free PMC article. Review.

5

Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications.

Banerjee S, Pillai MR, Knapp FF. Banerjee S, et al. Among authors: knapp ff. Chem Rev. 2015 Apr 22;115(8):2934-74. doi: 10.1021/cr500171e. Epub 2015 Apr 13. Chem Rev. 2015. PMID: 25865818 Review. No abstract available.

6

Phytosterol side chain biosynthesis.

Goad LJ, Lenton JR, Knapp FF, Goodwin TW. Goad LJ, et al. Among authors: knapp ff. Lipids. 1974 Aug;9(8):582-95. doi: 10.1007/BF02532508. Lipids. 1974. PMID: 4278900 Review. No abstract available.

7

99Mo/(99m)Tc separation: an assessment of technology options.

Dash A, Knapp FF Jr, Pillai MR. Dash A, et al. Among authors: knapp ff jr. Nucl Med Biol. 2013 Feb;40(2):167-76. doi: 10.1016/j.nucmedbio.2012.10.005. Epub 2012 Nov 9. Nucl Med Biol. 2013. PMID: 23142410 Review.

8

Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions.

Dash A, Das T, Knapp FFR. Dash A, et al. Among authors: knapp ffr. Curr Med Chem. 2020;27(19):3187-3249. doi: 10.2174/0929867326666190201142814. Curr Med Chem. 2020. PMID: 30714520 Review.

9

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Dash A, Pillai MR, Knapp FF Jr. Dash A, et al. Among authors: knapp ff jr. Nucl Med Mol Imaging. 2015 Jun;49(2):85-107. doi: 10.1007/s13139-014-0315-z. Epub 2015 Feb 17. Nucl Med Mol Imaging. 2015. PMID: 26085854 Free PMC article. Review.

10

Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.

Pillai AM, Knapp FF Jr. Pillai AM, et al. Among authors: knapp ff jr. Curr Radiopharm. 2016;9(1):6-7. Curr Radiopharm. 2016. PMID: 26655262 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results